CNBC June 18, 2024
Good morning! More U.S. employers are covering a buzzy class of medications called GLP-1s for weight loss, a survey found.
Roughly one-third of employer health plans in the U.S. said they are covering GLP-1 drugs like Novo Nordisk‘s Ozempic and Wegovy for both diabetes and weight loss, up from 26% last year.
GLP-1 drugs for weight loss also grew as a portion of employers’ overall annual medical claims spending, making up nearly 9% in 2024 compared to roughly 7% the year prior.
That’s according to the survey released Thursday by a nonprofit organization, the International Foundation of Employee Benefit Plans, which includes more than 33,000 member companies or public institutions. The survey was conducted in May on...
Today's Sponsors
Today's Sponsor